Olsalazine in ankylosing spondylitis: a pilot study.
OBJECTIVE. To test the safety and efficacy of olsalazine in men with ankylosing spondylitis (AS) unresponsive to nonsteroidal antiinflammatory drugs and physiotherapy. METHODS. Four patients, including 2 who had not responded to sulfasalazine (SASP) and one who did not tolerate SASP, were treated with olsalazine, up to 3 g/dl for 24 weeks. RESULTS. One patient discontinued olsalazine due to diarrhea at 1 g/day. The other 3 experienced improvement in global spine self assessment by visual analog scale (VAS), 2 of 3 patients, spinal pain (VAS, 3 of 3), night pain (3 of 3), tender joint count (3 of 3) and enthesis score (3 of 3). Changes in Schober's test and chest expansion were minor. Erythrocyte sedimentation rate and C-reactive protein were normal. Loose stools were the only adverse effects observed. CONCLUSION. Olsalazine appears to be well tolerated and effective in men with AS. Further study of olsalazine and direct comparison with SASP in this population may illuminate mechanisms of drug action and add a new therapeutic option.[1]References
- Olsalazine in ankylosing spondylitis: a pilot study. Chapman, C.M., Zwillich, S.H. J. Rheumatol. (1994) [Pubmed]
Annotations and hyperlinks in this abstract are from individual authors of WikiGenes or automatically generated by the WikiGenes Data Mining Engine. The abstract is from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenesOpen Access LicencePrivacy PolicyTerms of Useapsburg
